Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dorzolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 18/20 | 0.98 |
| ▸ | CA1 | P00915 | 3/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | CA3 | P07451 | 1/20 | 0.98 |
| ▸ | AR | P10275 | 1/20 | 0.98 |
| ▸ | CA4 | P22748 | 1/20 | 0.98 |
| ▸ | CA6 | P23280 | 1/20 | 0.98 |
| ▸ | CA5A | P35218 | 1/20 | 0.98 |
| ▸ | CA7 | P43166 | 1/20 | 0.98 |
| ▸ | CA9 | Q16790 | 1/20 | 0.98 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.98 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.98 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dorzolamide SCHEMBL41152 | 1.00 | CA2 (0.98) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL28388851 | 1.00 | CA2 (0.98) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL15545592 | 1.00 | CA2 (0.98) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL4525137 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL4455530 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL12223216 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL12874119 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL3306381 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL9914275 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR | |
| Dorzolamide SCHEMBL9914274 | 0.99 | CA2 (1.00) | CA2CA1CA12CA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094981-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO., INC. | 2002-07-18 | — | — | US | claimed |
| JP-2002501017-A | — | — | 2002-01-15 | — | — | JP | claimed |
| EP-1109546-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1100491-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2001-05-23 | — | — | EP | claimed |
| EP-1049466-A2 | CARBONIC ANHYDRASE INHIBITOR FOR INCREASING OXYGEN TENSION IN THE OPTIC NERVE AND RETINA | Merck Sharp & Dohme B.V. (NL) | 2000-11-08 | — | — | EP | claimed |
| EP-0998277-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-10 | — | — | EP | claimed |
| WO-2000004898-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2000-02-03 | — | — | WO | claimed |
| WO-2000004899-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2000-02-03 | — | — | WO | claimed |
| WO-1999037292-A2 | CARBONIC ANHYDRASE INHIBITOR FOR INCREASING OXYGEN TENSION IN THE OPTIC NERVE AND RETINA | MERCK SHARP & DOHME B.V. (NL) | 1999-07-29 | — | — | WO | claimed |
| WO-1998053809-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-9801813-B2 | Preservative-free ophthalmic pharmaceutical formulation | SENTISS PHARMA PRIVATE LIMITED (IN) | 2017-10-31 | — | — | US | disclosed |
| EP-3057576-A1 | PRESERVATIVE-FREE OPHTHALMIC PHARMACEUTICAL FORMULATION | Sentiss Pharma Private Limited (IN) | 2016-08-24 | — | — | EP | disclosed |
| US-20160235665-A1 | PRESERVATIVE-FREE OPHTHALMIC PHARMACEUTICAL FORMULATION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2016-08-18 | — | — | US | disclosed |
| WO-2015056149-A1 | PRESERVATIVE-FREE OPHTHALMIC PHARMACEUTICAL FORMULATION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2015-04-23 | — | — | WO | disclosed |
| US-8263787-B2 | Process for preparing dorzolamide | CIPLA LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| WO-2000004898-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-2000004899-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0932389-A1 | OPHTHALMIC COMPOSITIONS CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND XANTHAN GUM | LABORATOIRES MERCK SHARP & DOHME-CHIBRET SNC (FR) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998053809-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998017249-A1 | OPHTHALMIC COMPOSITIONS CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND XANTHAN GUM | LABORATOIRES MERCK SHARP & DOHME-CHIBRET SNC (FR) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094981-A1 | Ophthalmic compositions for treating ocular hypertension | PTGIS, CA2, PTGS1 | CA2 2/4885CA1 111/4885CA12 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.